Anthony Zook

Anthony P.
Zook is currently Chief Executive Officer & Director at NeoGenomics, Inc. starting in 2025, Chairman at Algorithm Sciences, Inc. since 2021, Executive Chairman at Voltron Therapeutics, Inc. since 2021, Independent Director at Adaptin Bio, Inc. starting in 2025, Trustee at Healthcare Leadership Council, and holds a position at Laidlaw Venture Partners since 2021.
Former roles include Interim Chief Executive Officer at MedImmune LLC, Chief Executive Officer & Director at VIVUS, Inc. in 2013, President & Chief Executive Officer at AstraZeneca Pharmaceuticals LP and Astra USA, Inc., Chief Executive Officer at Innocoll AG, Chief Executive Officer & Member-Supervisory Board at Innocoll Biotherapeutics Holdings Ltd. from 2017 to 2019, Chief Executive Officer at Innocoll Biotherapeutics from 2014 to 2015, Independent Director at Streamex Corp.
from 2020 to 2022, Director at Frostburg State University, Melinta Subsidiary Corp., American Cancer Society, Inc. Pennsylvania Division, Pharmaceutical Research & Manufacturers of America, National Pharmaceutical Council, First State Innovation, Inc., Inhibikase Therapeutics, Inc., AltheRx, Inc., ViralClear Pharmaceuticals, Inc., Executive Vice President-Global Commercial at AstraZeneca PLC from 2010 to 2013, President at MedImmune Ventures, Inc., and Partner at Lucius Partners LLC.
Education includes undergraduate studies at Frostburg State University and The Pennsylvania State University.